Migraines affect over 1 billion people globally and are one of the top causes of disability. Standard treatments often reduce migraine days by just 1–2 per month and come with side effects that lead many patients to stop treatment. Meanwhile, clinical-grade neuromodulation is effective but limited to hospitals, leaving a gap in accessible, personalized care.
Brightmind.ai delivers at-home migraine therapy through an AI-powered rTMS (repetitive Transcranial Magnetic Stimulation) device. It uses real-time EEG monitoring to predict migraines 24 hours in advance and personalize stimulation, reducing migraine days by over 6 per month. The solution is drug-free, non-invasive, and designed for daily, user-friendly use.
- Pilots: –
- Maturity: Clinical-stage prototype
- Capital raised: 3.3 M€
- Company Valuation: 4 M€
- Open Round: Yes
The device features a compact, energy-efficient coil and real-time brain monitoring. AI models forecast migraine risk and adjust therapy accordingly. Patients subscribe monthly via a digital platform. The technology is patent-pending and developed alongside leading neurologists.
- Sector: Health Tech
- Country: Austria
- Nº of workers: 7
